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Over the years, animal studies have revealed a role for the endocannabinoid system
in the regulation of multiple aspects of opiate addiction. The current review provides
an overview of this literature in regards to opiate withdrawal. The opiate withdrawal
syndrome, hypothesized to act as a negative reinforcer in mediating continued drug use,
can be characterized by the emergence of spontaneous or precipitated aversive somatic
and affective states following the termination of drug use. The behaviors measured to
quantify somatic opiate withdrawal and the paradigms employed to assess affective
opiate withdrawal (e.g., conditioned place aversion) in both acutely and chronically
dependent animals are discussed in relation to the ability of the endocannabinoid
system to modulate these behaviors. Additionally, the brain regions mediating somatic
and affective opiate withdrawal are elucidated with respect to their modulation by the
endocannabinoid system. Ultimately, a review of these findings reveals dissociations
between the brain regions mediating somatic and affective opiate withdrawal, and the
ability of cannabinoid type 1 (CB1) receptor agonism/antagonism to interfere with opiate
withdrawal within different brain sub regions.
Keywords: cannabinoid, opioid, withdrawal, animal, amygdala, nucleus accumbens, locus coeruleus,
periaqueductal gray
INTRODUCTION
Opiate addiction is a chronic distressing brain disorder for which there are limited successful
treatments that do not rely on the administration of synthetic opiate analogs (Stotts et al., 2009).
One potential non-opioidergic therapeutic target is the endocannabinoid system. A review of
the preclinical animal literature suggests that the endocannabinoid system is necessary for the
development of opiate dependence and could prove to be useful in the treatment of opiate
withdrawal.
CANNABINOIDS ON OPIATE WITHDRAWAL
In animals, as in humans, opioid dependence is produced through chronic opiate exposure, or
even, following the single administration of a high dose of an opiate, a state termed acute opiate
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dependence (Heishman et al., 1989; June et al., 1995). Once
dependent, withdrawal can be induced either spontaneously
through drug abstinence, or precipitated through the
administration of an opiate antagonist such as naloxone.
In each instance, dependent animals will display numerous
somatic and behavioral symptoms that are characteristic of the
withdrawal state experienced by human opiate addicts (Jaffe,
1990). The ability of different pharmacological manipulations
to alter the severity or presence of these symptoms can be
used as a measure of their potential in the treatment of opiate
detoxification.
Somatic Withdrawal
In animals, the intensity of somatic withdrawal is quantified
by scoring the presence or severity of several physical signs for
10–30 min immediately following precipitated withdrawal, or
every 6–9 h for several days following spontaneous withdrawal
(Maldonado et al., 1996). To facilitate the quantification of the
withdrawal syndrome, Gellert and Holtzman (1978) developed
a weighted scale consisting of graded symptoms including
percentage of weight loss, number of escape jumps, number
of wet dog shakes, number of abdominal constrictions, and
checked signs including diarrhea, facial fasciculations/teeth
chattering, swallowing, salivation, chromodacryorrhea, ptosis,
abnormal posture, erection/ejaculation/genital grooming,
and irritability. In assessing the ability of pharmacological
cannabinoid manipulations to alleviate the intensity of somatic
withdrawal, most studies use a variation of this scale to determine
whether individual signs or a global rating of withdrawal has
significantly decreased.
A review of the literature reveals that activation of the
cannabinoid system acutely prior to withdrawal, or chronic
inhibition of the system during the development of dependence,
is most effective in reducing withdrawal severity (see Table 1
for specific agonists and antagonists and original references).
In the majority of cases, acute treatment with a cannabinoid
agonist (in particular agonists of the CB1 receptor) immediately
prior to the induction of withdrawal in highly dependent animals
(whether precipitated or spontaneous) is able to attenuate several
aspects of the syndrome. Notably, a reduction in the incidence
of escape jumps, paw tremors, weight loss, and diarrhea were
most commonly reported in rodents (see Table 1 for original
references). Exceptions to the reductions in withdrawal occurred
only when the agonist (19THC) was administered chronically
during the development of morphine dependence (Cichewicz
and Welch, 2003; Gerak and France, 2016), when rats were made
acutely dependent on morphine prior to withdrawal (Hine et al.,
1975b), or when the cannabinoid tested, cannabidiol, was not a
CB1 receptor agonist (Hine et al., 1975d,e; Chesher and Jackson,
1985).
Somewhat contradictory, CB1 receptor knock-out (KO) mice
show reduced somatic opioid withdrawal and cannabinoid
antagonists (rimonabant and AM251) interfere with somatic
opioid withdrawal (see Table 1). However, contrary to the
cannabinoid agonists, antagonists were most effective in reducing
withdrawal when delivered chronically (not acutely) during
the development of opiate dependence. Indeed, when given
chronically prior to precipitating withdrawal with naloxone,
rimonabant and AM251 reliably reduced withdrawal severity
(Rubino et al., 2000; Mas-Nieto et al., 2001; Trang et al., 2006).
In contrast, when delivered acutely, antagonists were either
without effect (Navarro et al., 1998; Mas-Nieto et al., 2001;
Trang et al., 2006), or their ability to attenuate withdrawal
was markedly reduced (Trang et al., 2006). In a case of
spontaneous withdrawal (Navarro et al., 1998), acute rimonabant
treatment was even found to precipitate withdrawal in morphine-
dependent rats, however, this finding was not replicated when
tested in mice (Lichtman et al., 2001). Ultimately, these findings,
along with the results from the agonist studies, suggest that
the endocannabinoid system plays an important role in the
development of somatic opioid dependence and activation of the
system during withdrawal, or chronic blockade during opioid
dependence, can mitigate some of its adverse effects.
Unfortunately, CB1 receptor (CB1R) agonists and inverse
agonists/antagonists are known to produce undesirable side
effects (e.g., psychoactivity, depression) which limit their
therapeutic potential (Moreira et al., 2009). Therefore, it is
fortunate that non-psychoactive treatments (including Fatty Acid
Amide Hydrolase [FAAH] and monoacylglycerol lipase [MAGL]
inhibitors) which act to enhance endogenous cannabinoid tone
have also been effective in alleviating somatic withdrawal (see
Table 1 for specific agents and original references). While
inhibition of the MAGL enzyme (which elevates endogenous
2-arachidonoyl glycerol [2-AG]) produced the most robust
effects (Ramesh et al., 2011; Gamage et al., 2015), inhibitors
or KO mice of the catabolic FAAH enzyme (which elevates
endogenous anandamide [AEA]) reduced a subset of withdrawal
symptoms in most cases (Ramesh et al., 2011; Shahidi and
Hasanein, 2011), whereas the AEA transport inhibitor, AM404,
was without effect (Del Arco et al., 2002). However, unlike
FAAH inhibitors, MAGL inhibitors have been found to produce
cannabimimetic side effects (e.g., hypomotility, hyperreflexia;
Long et al., 2009) and can lead to the development of dependence
and tolerance with repeated administration (Schlosburg et al.,
2010). In light of this, Ramesh et al. (2013) and Gamage
et al. (2015) tested the combinations of low doses of FAAH
and MAGL inhibitors, or dual FAAH/MAGL inhibitors, for
their effectiveness in reducing withdrawal maximally without
additional side effects. Indeed, this combination of catabolic
enzyme inhibitors proved to be highly effective in reducing
withdrawal (including jumping, paw flutters, head shakes,
diarrhea, and weight loss) but was absent of adverse effects.
Consequently, when considering pharmacological interventions
that may aid in the treatment of somatic aspects of opiate
withdrawal, dual FAAH/MAGL inhibition (at low doses) is most
promising.
Affective Withdrawal
In animals, affective opioid withdrawal can be measured using
a number of motivational paradigms including the conditioned
place aversion (CPA), intracranial self-stimulation, and operant
responding for food (Maldonado et al., 1996). In evaluating
the role of the endocannabinoid system in affective opioid
withdrawal, the CPA paradigm has been most commonly
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TABLE 1 | Effect of different cannabinoid compounds on spontaneous or precipitated somatic and affective opioid withdrawal.
Cannabinoid compound Dosing Effect on
withdrawal
Animal Reference
Somatic Precipitated Agonists
AEA Acute Reduced Mice Vela et al., 1995
2-AG Acute Reduced Mice Yamaguchi et al., 2001
19 THC Acute Reduced Mice Gamage et al., 2015
Acute Reduced Mice Ramesh et al., 2011
Acute/co-chronic Reduced/enhanced Mice Cichewicz and Welch, 2003
Acute Reduced Mice Lichtman et al., 2001
Pre-chronic Reduced Mice Valverde et al., 2001
Acute Reduced Mice Vela et al., 1995
Acute Reduced Rats Chesher and Jackson, 1985†
Acute Reduced Rats Zaluzny et al., 1979†
Acute Reduced Mice Bhargava, 1976a,b
Acute/co-chronic Reduced Guinea Pigs/rats Frederickson et al., 1976
Acute Reduced/enhanced Rats Hine et al., 1975a,b,c,d,e
Acute No effect Rats Hine et al., 1975b
18 THC Acute Reduced Mice Yamaguchi et al., 2001
Acute Reduced Mice Bhargava, 1976a
11 hydroxy – 18 THC Acute Reduced Mice Bhargava, 1976a
CBD (non-CB1) Acute No effect Rats Chesher and Jackson, 1985†
Acute Reduced Mice Bhargava, 1976a
Acute No effect Rats Hine et al., 1975d,e
CBN Acute Reduced Rats Chesher and Jackson, 1985†
Acute Reduced Mice Bhargava, 1976a
Acute No effect Rats Hine et al., 1975d
HU-210 Acute Reduced Mice Yamaguchi et al., 2001
O-1602 (GPR55 agonist) Co-chronic Reduced Mice Alavi et al., 2016
AEA transport inhibitor
AM404 Acute No effect Mice Del Arco et al., 2002
FAAH inhibitors
PF-3845 Acute No effect Mice Gamage et al., 2015
Acute Reduced Mice Ramesh et al., 2011
URB-597 Acute Reduced Rats Shahidi and Hasanein, 2011
FAAH KO Reduced Mice Ramesh et al., 2011
MAGL inhibitor Gamage et al., 2015
JZL-184 Acute Reduced Mice Ramesh et al., 2011
Dual FAAH/MAGL
Inhibitors
SA-57 Acute Reduced Mice Gamage et al., 2015
JZL-184 + PF-3845 Acute Reduced Mice Ramesh et al., 2013
CB1 KO Reduced Mice Maccarrone et al., 2002
Reduced Mice Lichtman et al., 2001
Reduced Mice Ledent et al., 1999
CB1 antagonists/
inverse agonists
Rimonabant Acute/co-chronic Reduced aspects/
reduced
Rats Trang et al., 2006
Acute/co-chronic No effect/reduced Mice Mas-Nieto et al., 2001
Co-chronic Reduced/enhanced Rats Rubino et al., 2000
Acute No effect Rats Navarro et al., 1998
AM251 Acute/co-chronic No effect/reduced Rats Trang et al., 2006
(Continued)
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TABLE 1 | Continued
Cannabinoid compound Dosing Effect on
withdrawal
Animal Reference
Spontaneous Agonists
19 THC Co-chronic No effect Monkeys Gerak and France, 2016
Acute Reduced Dogs Gilbert, 1981
Nabilone Acute Reduced Dogs Gilbert, 1981
Nantradol Acute Reduced Dogs Gilbert, 1981
Acute Reduced Monkeys Young et al., 1981
Levonantradol Acute Reduced Monkeys Young et al., 1981
AEA transport inhibitor
AM404 Acute Reduced Mice Del Arco et al., 2002
MAGL inhibitor
JZL-184 Acute Reduced Mice Ramesh et al., 2011
Dual FAAH/MAGL inhibitors
SA-57 Acute Reduced Mice Ramesh et al., 2013
JZL-184 + PF-3845 Acute Reduced Mice Ramesh et al., 2013
CB1 antagonist/
inverse agonist
Rimonabant Acute Failed to precipitate Mice Lichtman et al., 2001
Acute Precipitated Rats Navarro et al., 1998
Affective CPA
paradigm
Agonists
19 THC Acute No effect Mice Gamage et al., 2015
FAAH inhibitors
PF-3845 Acute No effect Mice Gamage et al., 2015
Acute No effect Rats Wills et al., 2014
URB-597 Acute No effect Rats Wills et al., 2014
MAGL inhibitors
JZL-184 Acute No effect Mice Gamage et al., 2015
MJN110 Acute Reduced Rats Wills et al., 2014, 2016
Dual FAAH/MAGL inhibitor
SA-57 Acute No effect Mice Gamage et al., 2015
CB1 KO No effect Mice Martin et al., 2000
Reduced Mice Ledent et al., 1999
CB1 antagonists/
inverse agonists
Rimonabant Acute Precipitated Rats Navarro et al., 2001‡
AM251 Acute Reduced Rats Wills et al., 2014, 2016
CB1 neutral antagonist
AM4113 Acute Reduced Rats Wills et al., 2014
AM6527 Acute Reduced Rats Wills et al., 2014
Operant
responding
for food
CB1 antagonist/
inverse agonist
Rimonabant Acute Precipitated Rats Navarro et al., 2001‡
Dosing reflects whether compounds were given acutely prior to withdrawal, pre-chronic (chronically prior to morphine administration), or co-chronic (concurrently with
morphine during the development of dependence). Italicized rows indicate experiments tested on acutely dependent animals. †Quasi morphine withdrawal, ‡ spontaneous
withdrawal.
employed. This paradigm typically involves pairing naloxone-
precipitated morphine withdrawal (in acutely or chronically
dependent animals) with a specific environmental context,
such that, upon re-exposure to this context in a drug-free
state, animals will preferentially avoid the withdrawal paired
context versus a context that was previously paired with a
placebo saline injection (Sanchis-Segura and Spanagel, 2006).
This avoidance of the withdrawal context is used as a measure
of the intensity of the aversive affect experienced during
opioid withdrawal, and can be used to assess the potential
of pharmacological treatments to reduce affective withdrawal.
Indeed, pharmacological treatments that are currently used in
the treatment of opioid withdrawal (e.g., buprenorphine) are
effective in reducing the establishment of avoidance behavior
in this paradigm (Stinus et al., 2005). Also employed is the
operant responding for food paradigm (Navarro et al., 2001). In
Frontiers in Pharmacology | www.frontiersin.org 4 June 2016 | Volume 7 | Article 187
fphar-07-00187 June 27, 2016 Time: 12:32 # 5
Wills and Parker ECS in Opiate Withdrawal
this paradigm, a pharmacological treatment is deemed effective
in reducing affective withdrawal if it is able to suppress a
withdrawal-induced reduction in operant responding for food
(Maldonado et al., 1996).
A review of the literature reveals a more complicated role
for the endocannabinoid system in its ability to alleviate
affective opioid withdrawal than was observed for somatic
withdrawal (see Table 1); granted the studies conducted thus
far are fairly limited. Indeed, as with somatic withdrawal, both
activation and inhibition of the cannabinoid system has been
found effective in reducing affective opioid withdrawal, but
with greater inconsistencies. Contrary to somatic withdrawal,
the cannabinoid agonist, 19THC, and the FAAH enzyme
inhibitors, PF3845 and URB-597, tested were unable to modify
the establishment of a naloxone-precipitated CPA (Wills et al.,
2014; Gamage et al., 2015). However, while activation of the
cannabinoid system via exogenous cannabinoid administration
or endogenous elevation of AEA proved to have little efficacy,
inhibition of MAGL activity and concomitant elevation of 2-
AG showed mixed (Wills et al., 2014, 2016; Gamage et al.,
2015) but more promising results. Given that these discrepant
findings were obtained by different laboratories using different
procedures, compounds (JZL-184 vs. MJN110), and species (mice
vs. rats), more research into the potential of MAGL inhibition
in reducing affective opioid withdrawal will be required in
order to elucidate its role. Furthermore, while the only dual
FAAH/MAGL inhibitor (SA-57) investigated was unable to
modify a naloxone-precipitated CPA (Gamage et al., 2015),
additional research into the ability of such compounds to reduce
affective withdrawal should continue owing to their effectiveness
in reducing somatic withdrawal with minor adverse effects (noted
in previous section).
Although the deleterious reputation of cannabinoid
antagonists/inverse agonists may limit their therapeutic potential
(Bergman et al., 2008), blockade of the endocannabinoid system
may be effective for reducing affective opioid withdrawal.
Indeed, acute CB1R antagonism (with both AM251, and the
neutral CB1 antagonists, AM4113, and AM6527) was effective
in preventing the establishment of a naloxone-precipitated CPA
(Wills et al., 2014, 2016). This is in contrast to the ability of
acute CB1 antagonism to reliably reduce somatic withdrawal,
but could be attributed to the fact that the CPA paradigm may
provide a more sensitive measure of opioid withdrawal (Azar
et al., 2003). Of special consideration is that both antagonists
(which have been found to possess inverse agonist activity)
and neutral antagonists (void of intrinsic activity; Sink et al.,
2008) were effective in preventing the establishment of the CPA.
This is particularly important since these ‘neutral’ antagonists
have also been found to lack the adverse qualities attributed to
typical cannabinoid antagonists (Bergman et al., 2008). While the
only evaluations of chronic inhibition of the endocannabinoid
system (CB1 KO mice) yielded mixed results (Ledent et al., 1999;
Martin et al., 2000), chronic antagonism of the endocannabinoid
system during the development of dependence using ‘neutral’
antagonists should be investigated given that acute treatments
have been reported to precipitate both spontaneous affective and
somatic withdrawal (Navarro et al., 1998, 2001).
NEUROBIOLOGICAL CORRELATES AND
POTENTIAL MECHANISMS OF
INTERACTION
Although the exact mechanisms through which the endocan-
nabinoid system is able to modulate opioid withdrawal remain
to be elucidated, several theories have been proposed. Briefly,
it has been hypothesized that cannabinoid and opioids interact
through (1) reciprocal endogenous neurotransmitter/peptide
release, (2) common signal-transduction pathways, and (3)
receptor heterodimerization (see Parolaro et al., 2010; Scavone
et al., 2013, for a review). An overview of these mechanisms in the
brain regions most attributed to somatic and affective withdrawal
is discussed.
Somatic Withdrawal
The neuroanatomical substrates most sensitive to the appearance
of somatic opioid withdrawal include the periaqueductal gray
(PAG) and locus coeruleus (LC; see Maldonado et al., 1996,
for a review). Indeed, microinjection of methylnaloxonium,
a hydrophilic opiate antagonist, into these regions was most
sensitive in eliciting the opiate withdrawal syndrome, with
active symptoms such as jumping being particularly prominent
(Maldonado et al., 1992). In revisiting the withdrawal symptoms
most commonly attenuated by cannabinoid modulation (e.g.,
jumping and paw tremors), it becomes apparent that these
neuroanatomical substrates may represent regions through
which cannabinoids interact with the opioid system to attenuate
somatic withdrawal.
Much evidence indicates the PAG as a locus for cannabinoid–
opioid interactions. Indeed, anatomical immunolabeling has co-
localized the CB1R and µ-opioid receptor (MOR) within this
region. Furthermore, 8% of immunoreactive MOR PAG neurons
received immunoreactive CB1R appositions, indicating a role for
presynaptic cannabinoid modulation (Wilson-Poe et al., 2012).
In addition, sub-chronic CB1R agonist treatment with THC or
AM356 was reported to increase proenkephalin mRNA levels in
the PAG (Manzanares et al., 1998). A reciprocal effect following
repeated morphine treatment is also suggested given the ability
of the CB1R antagonist AM251 to increase the frequency of
spontaneous miniature inhibitory postsynaptic currents (IPSCs)
in morphine, but not saline treated animals, suggesting an
elevation of endocannabinoid tone (Wilson-Poe et al., 2014).
Chronic (up to 7 days) CB1R agonist treatment has also been
reported to up-regulate MOR density (Viganò et al., 2005),
with tolerance developing with prolonged (14 day) treatment
(Corchero et al., 2004). Finally, chronic THC pre-opiate exposure
or acute rimonabant treatment has been found to induce or
attenuate Fos immunoreactivity in the PAG from acute heroin or
morphine administration, respectively (Singh et al., 2004, 2005).
While the investigation of cannabinoid–opioid interaction in
the LC is less extensive than in the PAG, a recent anatomical study
confirmed the co-existence of MOR and CB1R immunoreactivity
in somatodendritic compartments of catecholaminergic neurons.
Additionally, as in the PAG, immunoreactive CB1R axon
terminals formed synaptic contacts with MOR dendrites
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(Scavone et al., 2010). Ultimately, these findings suggest a role
for cannabinoid–opioid interactions in the PAG and LC via
common signal transduction mechanisms, or potential receptor
heterodimerization given their close proximity and reports of
this occurrence (Schoffelmeer et al., 2006). Additionally, as
discussed above, interactions in endogenous neurotransmitter
release are also evident in the PAG. These mechanisms of
interaction correspond to the general ability of CB1R agonism or
chronic CB1R antagonism to reduce symptoms of somatic opioid
withdrawal.
Affective Withdrawal
The brain structures most sensitive to the motivating or
affective component of opioid withdrawal include the nucleus
accumbens (NAc) and the amygdala (see Maldonado et al.,
1996, for a review). Indeed, microinjection of hydrophilic opiate
antagonists into these regions was most sensitive in producing
the establishment of a CPA (Stinus et al., 1990), and suppressing
operant responding in morphine dependent rats (Koob et al.,
1989). An evaluation of cannabinoid–opioid interactions within
these regions also reveals these sites to be crucial in the ability of
the cannabinoid system to modulate affective opioid withdrawal.
There is substantial research supporting cannabinoid–
opioid interactions within the NAc. As in the PAG and LC,
immunolabeling has revealed evidence for CB1R and MOR
localization on the same neurons in the NAc shell and core,
as well as expression on synaptically linked neurons (Pickel
et al., 2004). Furthermore, CB1R and MOR allosterically
interact in this region causing non-additive and synergistic
effects on glutamate and GABA release, respectively. These
effects were reversed by their respective antagonists, but
antagonist co-administration blocked these antagonistic effects,
suggesting the potential for G-protein coupled heterodimeric
receptor complexes (Schoffelmeer et al., 2006). Consistent
with these findings, reports also suggest CB1R and MOR
synergy on cAMP/PKA signaling that is mediated through
βγ dimers (Yao et al., 2006). Chronic opioid and cannabinoid
administration has also been found to alter cannabinoid and
opioid stimulated G-protein receptor coupling, respectively;
though while cannabinoids enhance MOR binding (Viganò
et al., 2005), opioids have produced more mixed effects on
CB1R binding (Viganò et al., 2003, 2005; Fattore et al., 2007).
Reports of changes in receptor densities have also been noted,
with chronic opioid administration increasing CB1R density
(Gonzalez et al., 2002), mRNA and protein levels (Ren et al.,
2009), and cannabinoid agonist treatment increasing MOR
density (Corchero et al., 2004; Fattore et al., 2007; Molaei
et al., 2016). However, while cannabinoid agonists seem to
consistently increase MOR density, the effects of CB1R gene
deletion have been less consistent in reducing expressivity
(Urigüen et al., 2005; Lane et al., 2010). Cannabinoid–opioid
interactions on neuronal activation and dopamine release
have also been reported in the NAc. Indeed, cannabinoid
agonists increase while antagonists decrease Fos expression
induced by acute morphine (Singh et al., 2004, 2005), and
CB1R KO mice report decreased morphine-induced dopamine
release (Mascia et al., 1999). Finally, cross-talk on endogenous
neurotransmitter and peptide release has also been described,
with increased AEA and decreased 2-AG content following
chronic opioid administration, and increased Met-enkephalin
immunoreactivity (Valverde et al., 2001), proenkephalin mRNA
(Manzanares et al., 1998), and β-endorphin levels (Solinas
et al., 2004) following acute or chronic cannabinoid (THC or
CP-55,940) administration. These findings are consistent with
the ability of cannabinoid agonists to decrease affective opioid
withdrawal and provide evidence for interactions within the
NAc at the neurotransmitter, receptor and signal transduction
level.
A second region of interest attributed to mediating affective
opioid withdrawal is the amygdala. Although there is less research
investigating cannabinoid–opioid interactions within this region
in comparison to the NAc, effects on receptor density and
functionality have been noted. Specifically, acute and repeated
cannabinoid agonist (THC or WIN 55,212-2) administration
produced increases in MOR density and G-protein receptor
coupling in the amygdala (Corchero et al., 2004; Fattore et al.,
2007). Similar findings were also reported on the effects of
chronic opioid administration on CB1R density and receptor
coupling when considering the amygdala as a whole (Fattore
et al., 2007), however, decreases in CB1R density have been
described when analyzing the basolateral amygdala (BLA)
individually (Gonzalez et al., 2002). In addition to receptor
interactions, alterations in Fos immunoreactivity (Fos IR; a
marker of neuronal activation) have also been noted. Indeed,
acute treatment of the cannabinoid antagonist, rimonabant,
attenuated acute morphine-induced Fos immunoreactivity in the
amygdala as a whole (Singh et al., 2004), while investigations of
the central nucleus of the amygdala (CeA) specifically revealed
decreases in acute heroin-induced Fos IR following chronic
THC pre-treatment (Singh et al., 2005), and additive effects
on naloxone-induced Fos IR following acute THC exposure
(Allen et al., 2003). Although the above studies do not
make any direct comparisons between the BLA and CeA on
cannabinoid–opioid interactions, a recent experiment suggests
a functional double dissociation between these regions in the
ability of the cannabinoid system to modulate affective opioid
withdrawal. Indeed, cannabinoid agonism (via inhibition of
MAGL activity with MJN110) within the BLA, while cannabinoid
antagonism (AM251) within the CeA, is able to interfere with
the establishment of a naloxone-precipitated CPA in acutely
morphine dependent rats (Wills et al., 2016). Though the
mechanisms mediating the dissociation between these regions
were not investigated, this finding suggests potential differences
in cannabinoid–opioid modulation within different sub-regions
of the amygdala.
CONCLUSION
A review of the literature reveals that acute pharmacological
activation or chronic inhibition of the cannabinoid system
may interfere with opioid withdrawal. In particular, dual
FAAH/MAGL enzyme inhibitors or neutral CB1R antagonists are
most promising, though further investigations are necessary. In
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the central nervous system, cannabinoid–opioid interactions
are abundant and present within neuroanatomical regions
important in mediating opioid withdrawal including the
amygdala, the NAc, the PAG, and the LC. However, while
interactions have been described, more research on the
mechanisms through which endocannabinoid modulation is
able to attenuate opioid withdrawal will be required in order
to gain a more cohesive understanding of its therapeutic
potential.
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